MREO - Ultragenyx: Modest Sales Growth With Multiple Inflection Points Approaching
2024-06-06 15:42:20 ET
Summary
- Ultragenyx Pharmaceutical Inc. revenues from regulatory approved drugs in Q1 of 2024 were $109 million, representing sales growth of 8% compared to the same time period in 2023.
- Setrusumab is an anti-sclerostin monoclonal antibody being developed for the treatment of patients with osteogenesis imperfecta.
- DTX-401 is another promising program in the pipeline being developed for the treatment of patients with glycogen storage disease type Ia.
- Ultragenyx had $568.7 million in cash as of March 31st of 2024; enough cash to fund its operations for at least the next 12 months.
Ultragenyx Pharmaceutical Inc. ( RARE ) is a good long-term biotech to own in my opinion. That's because it has already been able to receive regulatory approvals for several of its drugs in its pipeline. Matter of fact, the drugs being sold by the company are Crysvita and Dojolvi....
Ultragenyx: Modest Sales Growth, With Multiple Inflection Points Approaching